AstraZeneca Writes Off $140 Million Following Product Trial

LONDON -- The shares of AstraZeneca  (LSE: AZN  ) (NYSE: AZN  ) added 6 pence to 3,359 pence during early London trade this morning after the company said it will write off $140 million following the outcome of a product trial.

The FTSE 100 member confirmed the charge related to the development of fostamatinib, an oral treatment for rheumatoid arthritis, and would be taken in the second quarter.

AstraZeneca said the results from a phase 3 test program, alongside data reported previously from earlier trials, had prompted the company not to proceed with regulatory filings for the product.

The blue chip also claimed that hypertension, diarrhea, nausea, headache, and nasopharyngitis were among the treatment's most commonly reported side effects.

AstraZeneca said it would now return the rights for fostamatinib to Rigel Pharmaceuticals.

Briggs Morrison, managing director, executive vice president of global medicines development and chief medical officer at AstraZeneca, said:

The results of the late stage trials did not measure up to the promising results we saw earlier in development. We remain committed to the search for new treatments for patients with rheumatic and inflammatory diseases with phase 2 compounds in rheumatoid arthritis and lupus and phase 3 compounds in gout and psoriasis.

AstraZeneca claimed the write-off would not affect its financial guidance for 2013, whereby revenues are predicted to fall between 5% and 10% and profits are projected to drop "significantly more."

However, a $2.80 -- or 185 pence -- per share dividend declared for 2012 currently supports a 5.5% yield.

Of course, whether that high income, this morning's $140 million write-off, as well as the wider prospects of pharmaceutical industry, all combine to make AstraZeneca a buy is something only you can decide.

However, if you already own AstraZeneca shares and are looking for more juicy income buying opportunities, this exclusive wealth report reviews five particularly attractive possibilities.

Indeed, all five opportunities offer a rich mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by the Fool as "5 Shares You Can Retire On"!

Just click here for your report -- it's free.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2470526, ~/Articles/ArticleHandler.aspx, 11/23/2014 2:11:11 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement